Literature DB >> 10359728

High-dose heparin impairs nitric oxide pathway and vasomotion in rats.

T Bachetti1, E Pasini, E Clini, G Cremona, R Ferrari.   

Abstract

BACKGROUND: Platelet-activating effects have been reported with high-dose heparin in acute thrombotic disorders. Recent studies have shown that increased platelet aggregation is due to reduced nitric oxide (NO) production in endothelial cells cultured in the presence of high-dose heparin. The aim of this study was to determine whether heparin can affect the NO pathway and the regulation of the vascular tone in vivo. METHODS AND
RESULTS: Anesthetized and mechanically ventilated Sprague-Dawley rats were treated with high-dose heparin. After 4 hours, the endothelial constitutive NO synthase (ecNOS) protein content in the aorta decreased (36% reduction, P<0.05), as detected by immunoblotting, and NO-dependent vascular reactivity was impaired. In fact, the increase in mean arterial blood pressure after inhibition of ecNOS with NG-nitro-L-arginine methyl ester (30 mg/kg) was smaller in heparin-treated animals than in controls (+26. 9+/-4.8 versus +48.3+/-9.1 mm Hg, P<0.05), and further infusion of the biological ecNOS substrate L-arginine (0.5 g/kg) was ineffective in reversing systemic vasoconstriction (-1% versus 28% vasodilatation, P<0.001).
CONCLUSIONS: High-dose heparin can significantly affect vascular reactivity in vivo by downregulation of ecNOS protein expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359728     DOI: 10.1161/01.cir.99.22.2861

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  2 in total

1.  Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-dependent pathways.

Authors:  Hui Xie-Zukauskas; Jharna Das; Billie Lou Short; J Silvio Gutkind; Patricio E Ray
Journal:  Vascul Pharmacol       Date:  2012-12-23       Impact factor: 5.773

2.  Heparanase inhibition preserves the endothelial glycocalyx in lung grafts and improves lung preservation and transplant outcomes.

Authors:  Kentaro Noda; Brian J Philips; Mark E Snyder; Julie A Phillippi; Mara Sullivan; Donna B Stolz; Xi Ren; James D Luketich; Pablo G Sanchez
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.